Cargando…

Dual antiplatelet therapy with ticagrelor may increase the risk of all bleeding events in patients with minor strokes or high risk TIAs: a meta-analysis

Detalles Bibliográficos
Autores principales:	Chen, Xi, Xu, Jiawen, Chen, Shidong, Dong, Qiang, Dong, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453826/ https://www.ncbi.nlm.nih.gov/pubmed/35241629 http://dx.doi.org/10.1136/svn-2021-001423

Ejemplares similares

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)

Effect of dual antiplatelet on recurrent stroke in minor stroke or TIA depends on bodyweight
por: Ma, Yan, et al.
Publicado: (2018)

Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Reactivity in Patients With Minor Stroke or TIA
por: Yang, Yingying, et al.
Publicado: (2020)

Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO Trial
por: Lee, Yong-Joon, et al.
Publicado: (2021)

Effect of ticagrelor versus clopidogrel on platelet reactivity measured by thrombelastography in patients with minor stroke or TIA
por: Yang, Yingying, et al.
Publicado: (2020)

The role of ticagrelor in acute ischaemic stroke and high-risk TIA management
por: MacIver, Claire, et al.
Publicado: (2020)

European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA
por: Dawson, Jesse, et al.
Publicado: (2021)

European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA
por: Dawson, Jesse, et al.
Publicado: (2021)

Different levels of blood pressure, different benefit from dual antiplatelet therapy in minor stroke or TIA patients
por: Xu, Jie, et al.
Publicado: (2017)

Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial
por: Wangqin, Runqi, et al.
Publicado: (2017)

Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice
por: Mullen, Liam, et al.
Publicado: (2021)

Dual Antiplatelet Therapy and the Severity Risk of Lower Intestinal Bleeding
por: Carlin, Neal, et al.
Publicado: (2017)

Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke
por: Hilkens, Nina A., et al.
Publicado: (2018)

Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013)

Dual-Antiplatelet Therapy May Not Be Associated With an Increased Risk of In-hospital Bleeding in Patients With Moderate or Severe Ischemic Stroke
por: Khazaal, Ossama, et al.
Publicado: (2021)

Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial
por: Wang, David, et al.
Publicado: (2016)

Risk of bleeding in patients with continued dual antiplatelet therapy during orthopedic surgery
por: Hu, San-Bao, et al.
Publicado: (2019)

Thrombotic vs. Bleeding Events of Interruption of Dual Antiplatelet Therapy within 12 Months among Patients with Stent-Driven High Ischemic Risk Definition following PCI
por: Wang, Hao-Yu, et al.
Publicado: (2022)

Spontaneous subdural hematoma and antiplatelet therapy: Does efficacy of Ticagrelor come with added risk?
por: Suryanarayana Sharma, Pattanagere Manjunatha, et al.
Publicado: (2015)

Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction
por: Yeh, Jong-Shiuan, et al.
Publicado: (2023)

Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010)

Ticagrelor: The first approved reversible oral antiplatelet agent
por: Goel, Divya
Publicado: (2013)

Early Identification of High-Risk TIA or Minor Stroke Using Artificial Neural Network
por: Chan, Ka Lung, et al.
Publicado: (2019)

Microalbuminuria could improve risk stratification in patients with TIA and minor stroke
por: Elyas, Salim, et al.
Publicado: (2016)

The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel
por: Choi, Woong Gil, et al.
Publicado: (2021)

Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review
por: Tsigkas, Grigorios, et al.
Publicado: (2023)

Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
por: Marczewski, Margaret M, et al.
Publicado: (2010)

Dual Antiplatelet Therapy in Patients With Minor Stroke Receiving Intravenous Thrombolysis
por: Xu, Zhaohan, et al.
Publicado: (2022)

Retrospective analysis of the bleeding risk induced by oral antiplatelet drugs during radiotherapy
por: Xi, Dan, et al.
Publicado: (2021)

Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention
por: Pelliccia, Francesco, et al.
Publicado: (2022)

Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
por: Condello, Francesco, et al.
Publicado: (2021)

Retinal microvascular signs and recurrent vascular events in patients with TIA or minor stroke
por: Klyscz, Philipp, et al.
Publicado: (2023)

Elevated Neutrophil to Lymphocyte Ratio Associated With Increased Risk of Recurrent Vascular Events in Older Minor Stroke or TIA Patients
por: Chan, Ka Lung, et al.
Publicado: (2021)

Ticagrelor or clopidogrel dual antiplatelet therapy following a pharmacoinvasive strategy in ST‐segment elevation myocardial infarction
por: Welsh, Robert C., et al.
Publicado: (2021)

The stent in the high-bleeding risk patient: antiplatelet monotherapy?
por: Capranzano, Piera
Publicado: (2022)

Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk
por: Tjerkaski, Jonathan, et al.
Publicado: (2023)

Age‐Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial
por: Kim, Byung Gyu, et al.
Publicado: (2021)

Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk
por: Park, Keun-Ho, et al.
Publicado: (2021)

Thrombin Generation as a Method to Identify the Risk of Bleeding in High Clinical-Risk Patients Using Dual Antiplatelet Therapy
por: de Breet, C. P. D. M., et al.
Publicado: (2021)

The impact of dual antiplatelet therapy administration on the risk of bleeding complications during coronary artery bypass surgery
por: Nardi, Paolo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l4uceqnpug0mv9hsh8s17rq2no